We're joined once again with CEO Dennis Hancock and Director of Life Sciences Michael Farber to discuss Mountain Valley MD's (CSE:MVMD / OTCQB:MVMDF) much anticipated cold chain results. We touch on what the next steps are with this lane, why its important to reach 40C stabilization, near term revenue deals to be looking out for, how to pivot for the tIPV dose sparing adjuvant and finally what investors should be excited about coming down the pipeline.
Important Elements
0:21 - The implications that solving cold chain has on both Mountain Valley as a company, but for the medical community as a whole
1:57 - How successfully stabilizing and preserving serotype 2 of the Trivalent Inactivated Poliovirus Vaccine (tIPV) validates their approach to fully breaking cold chain and preserve tIPV at 40C for min of 3 days across all 3 serotypes
4:27 - A reminder that MVMD has already successfully preserves all 3 serotypes at 30C, and why its so important to achieve that extra 10C to 40C to qualify under the WHOS guidelines for Controlled Temperature Chain (CTS)
5:35 - Does the success of serotype 2 now enable MVMD to begin pointing this science towards other vaccines? Or is the goal to first ensure all 3 serotypes pass the CTC guidelines?
6:52 - The importance of choosing IPV as the first target for cold chain due to its high level of heat instability. Prove this, prove a multitude of other vaccines in similar or lower level of heat instability
7:33 - Discussing the need to adjust the IPV Dose Sparing Adjuvant testing, and how they believe they now know how to re-approach this lane in their next set of testing
9:02 - Reminder on how Dose Sparing for MVMD comes in numerous forms outside of singling in on the IPV dose sparing adjuvant
11:43 - Mike embarks some wisdom on how sometimes the road to the discovery is just as important as the discovery itself
13:10 - Dennis takes a moment to discuss on the current share price and the road ahead for this stock
17:38 - The pathway to revenues and what investors can expect in the near term
19:17 - The numerous elements that investors should be excited about that is currently being working on by MVMD and what is quickly coming down the pipeline
0 Comments